title: Glypican-3 antibodies: a new therapeutic target for liver cancer.
abstract: Glypican-3 (GPC3) is an emerging therapeutic target in hepatocellular carcinoma (HCC), even though the biological function of GPC3 remains elusive. Currently human (MDX-1414 and HN3) and humanized mouse (GC33 and YP7) antibodies that target GPC3 for HCC treatment are under different stages of preclinical or clinical development. Humanized mouse antibody GC33 is being evaluated in a phase II clinical trial. Human antibodies MDX-1414 and HN3 are under different stages of preclinical evaluation. Here, we summarize current evidence for GPC3 as a new target in liver cancer, discuss both its oncogenic function and its mode of actions for current antibodies, and evaluate potential challenges for GPC3-targeted anti-cancer therapies.
authors.affiliation: Antibody Therapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Mingqian
authors.initials: M
authors.lastname: Feng
authors.affiliation: Antibody Therapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: homi@mail.nih.gov.
authors.forename: Mitchell
authors.initials: M
authors.lastname: Ho
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology* / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000276:immunology; D053673:Glypicans / Q000276:immunology*; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods*
chemical_list: D000906:Antibodies; D014408:Biomarkers, Tumor; D053673:Glypicans
keywords: GC33; Glypican-3 (GPC3); HN3; Heparan sulfate proteoglycan; Hepatocellular carcinoma; YP7